Related by context. All words. (Click for frequent words.) 75 CIMZIA TM 74 atazanavir ritonavir 74 mcg kg 74 dose cohort 73 mg dose 72 mcg BID 72 hematologic toxicity 72 mcg dose 71 #mg BID [001] 71 mg QD 71 mCi kg 71 mg/m2 dose 71 IFN α 71 mg TID 71 APTIVUS r 71 mg BID 71 mcg albinterferon alfa 2b 71 LPV r 71 biochemical relapse 71 clodronate 70 dose cohorts 70 ALT flares 70 timepoints 70 octreotide LAR 70 docetaxel chemotherapy 70 posaconazole 70 4mg/kg 70 virologic failure 70 5-FU/LV 70 tipranavir r 70 HBeAg seroconversion 70 definite stent thrombosis 70 lopinavir r 70 Peg IFN 70 evaluable subjects 70 ug kg 70 mcg Albuferon 70 CR CRu 70 DLTs 70 PASI scores 70 desvenlafaxine succinate 70 HBeAg positive patients 70 mg ustekinumab 70 adefovir 70 comparator arm 70 severe neutropenia 69 8mg/kg 69 plus dexamethasone 69 μg kg 69 peginterferon alfa 2b 69 serum HCV RNA 69 intravenous dosing 69 mg kg 69 CIMZIA ™ 69 mg/m2/day 69 dosing cohort 69 piperacillin tazobactam 69 chlorambucil 69 serum HBV DNA 69 decitabine 69 CCyR 69 doxorubicin docetaxel 69 oral allopurinol 69 virological response 69 #mg/m# [002] 69 q#h 68 virological failure 68 ribavirin RBV 68 adalimumab 68 PREZISTA r 68 recurrent glioblastoma multiforme 68 pomalidomide 68 HBeAg negative patients 68 cis retinoic acid 68 tapentadol ER 68 detectable HCV RNA 68 μg dose 68 PegIFN RBV 68 FOLFOX4 68 low dose cytarabine 68 5FU 68 #mg dose [001] 68 mitoxantrone 68 mcg doses 68 microgram kg 68 ritonavir boosted 68 receiving VICTRELIS 68 FOLFOX 68 timepoint 68 median PFS 68 lopinavir r arm 68 plasma uric acid 68 rapid virologic response 68 evaluable 68 ritonavir boosted lopinavir 68 undetectable HCV RNA 68 mcg mL 68 virologic response 68 genotypic resistance 68 #mg BID [003] 68 LEXIVA r 68 ABC/3TC 68 mcg QD 68 #mg QD [001] 68 baseline HbA1c 68 TMC# r 68 IFN beta 68 relapsed MM 68 #mg/m# [001] 68 EDSS scores 68 R# #mg BID 68 undetectable HBV DNA 68 GnRH agonist 68 evaluable patients 68 achieved PASI 68 REYATAZ r arm 68 QTcF 68 MGd 68 doxorubicin cyclophosphamide 68 elevated ALT 68 patients evaluable 68 log# copies mL 68 #mg/day [002] 68 antibody titers 68 ULORIC 68 DAPT 67 dosing cohorts 67 flutamide 67 splenectomized patients 67 pCR 67 KRAS mutations occur 67 teriflunomide 67 abacavir lamivudine 67 #mg QD [002] 67 CsA 67 nab paclitaxel 67 Solid Tumors criteria 67 HBeAg positive 67 dexamethasone Decadron 67 nelfinavir 67 HIV RNA 67 FOLFIRI 67 achieved ACR# 67 FOLPI 67 sustained virologic response 67 #mg doses [002] 67 lymphocytosis 67 seroprotection 67 sunitinib 67 mycophenolate mofetil 67 goserelin 67 recurrent VTE 67 certolizumab 67 TNF antagonist 67 carboplatin paclitaxel 67 peginterferon alfa 2a 67 peg IFN 67 plus methotrexate 67 log# reduction 67 SVR# 67 complete cytogenetic 67 insulin detemir 67 placebo dexamethasone 67 saline placebo 67 alteplase 67 μmol L 67 #mg/day [001] 67 intravenous bolus 67 administered subcutaneously 67 caspofungin 67 serum urate 67 rFVIIa 67 rFSH 67 peginterferon 67 postintervention 67 alanine aminotransferase 67 VELCADE melphalan 67 aprepitant 67 IFN alfa 67 ropivacaine 67 nadroparin 67 CR nPR 67 mg/m2 67 treatment naive genotype 67 Doxil ® 67 HCV RESPOND 2 67 pegylated interferon alpha 67 otamixaban 67 darunavir ritonavir 67 tacrolimus ointment 66 azacitidine 66 Vectibix monotherapy 66 androgen suppression 66 HBV DNA 66 isoproterenol 66 μg ml 66 complete cytogenetic response 66 NATRECOR R 66 imatinib therapy 66 pegylated interferon alfa 2b 66 p = NS 66 CANCIDAS 66 Elitek 66 PSA nadir 66 corticosteroid dose 66 Traficet EN 66 androgen deprivation 66 FluCAM 66 Kaplan Meier analysis 66 intramuscularly 66 virologic breakthrough 66 antiandrogen 66 EDSS score 66 neurologic progression 66 solifenacin 66 lumbar spine BMD 66 #mg/kg [002] 66 telaprevir dosed 66 NNRTI resistance 66 ACR# response 66 clinically meaningful improvement 66 achieved CCyR 66 binary restenosis 66 cytogenetic response 66 idraparinux 66 Flu Cy 66 Bezielle 66 pegylated liposomal doxorubicin 66 transaminase elevations 66 brivaracetam 66 PEG IFN 66 NLX P# 66 intermittent dosing 66 uM 66 bolus dose 66 mg qd 66 serum cortisol 66 plus ribavirin 66 EXJADE 66 mapatumumab 66 XELOX 66 corticosteroid therapy 66 rhEPO 66 apremilast 66 divalproex sodium 66 crizotinib PF # 66 plasma HCV RNA 66 cisplatin vinorelbine 66 adjunctive placebo 66 oral prednisone 66 SCIg 66 Fludara 66 intravitreal injection 66 adriamycin 66 dose dexamethasone 66 aspartate aminotransferase 66 GSK# [001] 66 #mg dose [002] 66 pg ml 66 prucalopride 66 unfractionated heparin 66 cilengitide 66 methotrexate monotherapy 66 azacytidine 66 intravesical 66 heavily pretreated 66 amoxicillin clavulanate 66 BEACOPP 66 infliximab 66 serum concentrations 66 #mg dose [003] 66 Ceplene/IL-2 66 aspartate aminotransferase AST 66 salmeterol fluticasone 66 tocilizumab 66 mg m² 66 dosage regimens 66 neostigmine 66 ascending dose 66 weekly subcutaneous injections 66 interferon alfa 66 ancrod 66 ribavirin therapy 65 HCV genotype 65 dapagliflozin plus 65 bendamustine 65 abiraterone acetate 65 bortezomib refractory 65 febrile neutropenia 65 HCV SPRINT 65 placebo p = 65 HbA 1c levels 65 mg kg hr 65 irbesartan 65 aminotransferase levels 65 follicular lymphomas 65 ximelagatran 65 ziprasidone 65 low dose Iluvien 65 posttreatment 65 moderately emetogenic 65 alanine aminotransferase ALT 65 abnormal p# biomarker 65 Tarceva TM 65 aPTT 65 mcg kg min 65 daunorubicin 65 rHuEPO 65 vicriviroc 65 Aptivus ® 65 TEAEs 65 thromboembolic events 65 fosamprenavir 65 Cmax 65 RECIST Response Evaluation Criteria 65 PREZISTA ritonavir 65 chemoradiation therapy 65 mCi 65 MCyR 65 estramustine 65 EBRT 65 ertapenem 65 eplerenone 65 temsirolimus 65 oxycodone CR 65 ug mL 65 biochemical recurrence 65 anti HBs 65 mCRC patients 65 lispro 65 IU ml 65 diuretic chlorthalidone 65 elotuzumab 65 platelet reactivity 65 peg interferon 65 n = 65 postoperative chemotherapy 65 prior chemotherapy regimens 65 DOXIL 65 CHOP chemotherapy 65 fluorouracil 65 dalteparin 65 log# 65 hours postdose 65 prospectively defined 65 nadolol 65 methotrexate therapy 65 mg d 65 mIU mL 65 CLL SLL 65 LMWH 65 HCV RNA 65 nitazoxanide 65 rizatriptan 65 periprocedural 65 interferon alfa 2b 65 mRCC 65 lanthanum carbonate 65 abatacept 65 HBV DNA levels 65 ibandronate 65 RECIST criteria 65 pamidronate 65 epoetin alfa 65 viral kinetics 65 achieved sustained virological 65 mg kg cohorts 65 partial remissions 65 active comparator 65 degarelix 65 q8h 65 RLAI 65 gemcitabine carboplatin 65 mesalamine granules 65 tirofiban 65 neutrophil counts 65 ascending doses 65 heavily pretreated patients 65 anastrazole 65 antibody titer 65 certolizumab pegol 65 tipranavir ritonavir 65 glycated hemoglobin levels 65 anti leukemic 65 MAS XR 65 daily subcutaneous injections 65 bicalutamide 65 HGPIN 65 MabCampath 65 serum phosphorus 65 achieved statistical significance 65 gadobutrol 65 serum testosterone 65 glatiramer acetate 65 unfractionated heparin UFH 65 HSCT 65 PRADAXA #mg 65 iniparib BSI 65 GAMMAGARD 64 MACCE 64 mCi m 2 64 octreotide 64 mg BID dose 64 PROMACTA 64 #mg BID [002] 64 cilostazol 64 microg 64 imetelstat 64 P = .# 64 RGT arm 64 annualized relapse 64 PSMA ADC 64 mg doses 64 mITT population 64 etanercept 64 KRAS mutant tumors 64 bosentan 64 steroid dexamethasone 64 dose escalation phase 64 NPH insulin 64 BARACLUDE ® 64 rotigotine 64 lamivudine monotherapy 64 pegaptanib 64 sustained virological response 64 blinded randomized placebo controlled 64 placebo controlled clinical trials 64 lacosamide 64 oral rivaroxaban 64 oblimersen 64 dose cytarabine 64 TORISEL 64 VIRAMUNE 64 insulin degludec 64 seropositive patients 64 mmol kg 64 topotecan 64 neoadjuvant chemotherapy 64 nonresponders 64 chemoradiotherapy 64 paraprotein 64 rimonabant #mg 64 standard chemotherapy regimen 64 QTc prolongation 64 ACTEMRA TM 64 Xelox 64 QD dosing 64 tinzaparin 64 oral diclofenac 64 FOLFIRI alone 64 severe exacerbations 64 Folfox 64 hypokalemia 64 virologic responses 64 comparator PI r 64 prespecified 64 Median progression 64 pharmacokinetics PK 64 intravenous bisphosphonates 64 liver metastases 64 leukocyte count 64 antithymocyte globulin 64 aminotransferases 64 Median PFS 64 AZT zidovudine Retrovir 64 dose titration 64 CYPHER Stent 64 gastrointestinal toxicities 64 Dose escalation 64 timolol 64 metastatic RCC 64 squamous histology 64 alfa 2a 64 clomipramine 64 fluvastatin 64 pentoxifylline 64 olmesartan 64 paricalcitol 64 cabazitaxel 64 STELARA 64 idarubicin 64 HBeAg 64 EGFR TKI 64 pyrazinamide 64 ZOLINZA 64 pg mL 64 APTIVUS 64 peginterferon alfa 2a #KD 64 virologic 64 Engerix B 64 biologic DMARD 64 progression TTP 64 amphotericin B 64 Platelet counts 64 MAGE A3 ASCI 64 systemic corticosteroids 64 lymphopenia 64 forodesine 64 fondaparinux 64 subcutaneous doses 64 noninferiority 64 urate lowering therapy 64 docetaxel prednisone 64 avosentan 64 venlafaxine XR 64 mutated KRAS 64 interferon ribavirin 64 dose escalation 64 dose regimens 64 weekly intravenous infusions 64 metformin monotherapy 64 VFEND 64 tolterodine 64 Teriflunomide 64 YERVOY 64 CIMZIA TM certolizumab pegol 64 systemically administered 64 baseline LDH 64 specific antigen PSA 64 bolus injection 64 PRECiSE 64 PegIFN 64 ethambutol 64 MULTAQ 64 VAPRISOL 64 GHRH 64 serum calcium levels 64 tipranavir 64 plasma cortisol 64 μg mL 64 % Confidence Interval 64 injected subcutaneously 64 highly emetogenic 64 p = #.# [003] 63 subcutaneously administered 63 pegylated interferon alfa 63 -#.# log# 63 TDF FTC 63 telaprevir dosing 63 HER2 expression 63 riociguat 63 HER2 amplification 63 fluticasone salmeterol 63 events AEs 63 β blockers 63 axitinib 63 TNF α 63 GOUT 63 response CCyR 63 ACR# responses 63 fluorouracil leucovorin 63 rapid virological response 63 % CI #.#-#.# [003] 63 Response Evaluation Criteria 63 % CI #.#-#.# [007] 63 remission CR 63 glufosfamide 63 antiretroviral naive 63 SCCHN 63 Pharmacokinetic parameters 63 FFNS 63 FluCAM arm 63 quetiapine 63 serum ALT 63 imipenem 63 interquartile range 63 REYATAZ r 63 melphalan prednisone 63 seliciclib 63 Dasatinib 63 metastatic CRC 63 vandetanib 63 anemia hemoglobin 63 allogeneic SCT 63 infliximab therapy 63 bortezomib 63 experienced virologic failure 63 mg RDEA# 63 transaminases 63 PegIntron 63 Pred Forte 63 Free Survival PFS 63 hypophosphatemia 63 argatroban 63 SUVmax 63 seroconversion 63 fibrinolysis 63 NAbs 63 ALT elevation 63 dasatinib 63 mdx mice 63 QT QTc 63 ACTH 63 pretreatment baseline 63 paclitaxel cisplatin 63 laboratory abnormalities 63 undetectable viral 63 vinorelbine 63 cisplatin chemotherapy 63 NEUPOGEN 63 RRMS patients 63 INCB# [003] 63 rt PA 63 CD# upregulation 63 plus medroxyprogesterone acetate 63 nmol 63 adenoma recurrence 63 EURIDIS 63 coadministration 63 serum estradiol 63 HBeAg negative 63 ALVESCO 63 tolvaptan 63 liver biopsies 63 pharmacodynamic 63 zoledronic acid 63 neutropenic fever 63 plus prednisone 63 pegIFN 63 ara C 63 placebo p 63 Median survival 63 tenofovir emtricitabine 63 IFN alpha 63 alkylating agent 63 5-fluorouracil/leucovorin 63 pheochromocytoma 63 anagrelide 63 dacarbazine 63 insulin glargine 63 discontinuations due 63 #mg ATC 63 Index CDAI 63 zonisamide SR 63 â ‰ ¥ 63 postoperatively 63 IV NSCLC 63 ketorolac 63 leucopenia 63 peginterferon alfa 63 Pegasys ® 63 intraperitoneal 63 zolmitriptan 63 statin monotherapy 63 ketoconazole 63 Phase 2a trial 63 alefacept 63 HbA1c levels 63 imatinib 63 urocortin 2 63 undergone splenectomy 63 statistically significant p = 63 pT3 63 darbepoetin alfa 63 ritonavir boosted atazanavir 63 LAB GHRH 63 tumor regressions 63 subcutaneous injections 63 ARB telmisartan 63 pooled comparator 63 fluticasone furoate 63 PSADT 63 anakinra 63 IV bolus 63 favorable pharmacokinetic profile 63 ipsilateral stroke 63 sitagliptin 63 adalimumab Humira 63 reinfarction 63 micafungin 63 MIRCERA 63 subcutaneous dose 63 symptomatic VTE 63 dosed orally 63 median survivals 63 monoinfected patients 63 preoperative chemotherapy 63 underwent surgical resection 63 verteporfin 63 KRAS status 63 lung metastases 63 gemcitabine cisplatin 63 TELCYTA 63 pharmacodynamic PD 63 alemtuzumab treated 63 Wistar rats 63 AST ALT 63 morphometric vertebral fractures 63 romiplostim 63 mitomycin C 63 Subgroup analysis 63 Crohn Disease Activity 63 fulvestrant 63 ARCOXIA 63 3mg/kg 63 budesonide foam 63 GVAX 63 ALT elevations 63 serum phosphate levels 63 intramuscular dose 63 achieving PASI 63 IIIa inhibitor 63 ARIXTRA 63 PRADAXA 63 enfuvirtide 63 curative resection 63 placebo 63 refractory NSCLC 63 tumor regression 63 chronic HCV genotype 63 microbiological eradication 63 INVEGA ® 63 TACE 63 pramipexole 63 Pemetrexed 63 hypercalcemia 63 GPIIb IIIa 62 nephrotoxicity 62 IL 1ß 62 Natalizumab 62 lamivudine refractory patients 62 HBsAg 62 neutropaenia 62 nM 62 lenalidomide dexamethasone 62 inhaled budesonide 62 DAS# CRP 62 Cytoxan 62 C1 INH 62 titration phase 62 canakinumab 62 mepolizumab 62 inotropic 62 peripheral blood mononuclear 62 HGS ETR1 62 tolterodine ER 62 esomeprazole 62 mg/# h 62 MADRS score 62 μg doses 62 DFMO 62 mg eq 62 iloprost 62 adefovir dipivoxil 62 TIMP 1 62 NIHSS 62 rindopepimut 62 vidofludimus 62 log# IU mL 62 XIENCE V PROMUS Stent 62 serum urate levels 62 perampanel 62 ng dl 62 NRTI 62 colorectal carcinomas 62 mg Proellex 62 valopicitabine 62 serum creatinine levels 62 rhGH 62 hA# 62 prednisone prednisolone 62 receptor tyrosine kinase inhibitor 62 free survival PFS 62 neoadjuvant 62 TroVax ® 62 intravitreal injections 62 inhibitor RG# 62 iodixanol 62 metastatic HRPC 62 calcineurin inhibitor 62 dosing intervals 62 MBq 62 tumor recurrence 62 perioperatively 62 Decitabine 62 viral titers 62 urate lowering 62 complete remissions 62 ng dL 62 mU liter 62 resected pancreatic cancer 62 leukemia AML 62 CCR5 tropic HIV 62 etoposide 62 PreCISe study 62 sirolimus 62 placebo controlled clinical 62 concurrent chemoradiation 62 mg/m2 cohort 62 NEVO ™ 62 glomerular filtration 62 intratumoral injection 62 intraocular inflammation 62 LHRH agonists 62 abciximab 62 mg m 62 levetiracetam 62 immunomodulatory therapy 62 dose colchicine 62 gout flares 62 stage IIIB 62 intratumoral 62 hepatic enzymes 62 Amrubicin 62 doripenem 62 EMPHASIS HF trial 62 d4T 62 undetectable virus HCV 62 Durezol 62 IOP lowering 62 antitumor effect 62 huN# DM1 62 AGILECT R 62 #mmHg [001] 62 ug dose 62 valacyclovir 62 nephrectomy 62 HCV genotypes 62 plasma glucose 62 tumor shrinkage 62 BYSTOLIC 62 T2DM 62 titrated glipizide 62 sitaxsentan 62 clinically meaningful improvements 62 poor metabolizers 62 pimecrolimus cream 62 primary patency 62 serum IGF 62 dose limiting toxicities 62 continuous intravenous infusion 62 gefitinib 62 concomitant antibiotics 62 elevated transaminases 62 tamoxifen therapy 62 angiographic outcomes 62 adjuvant radiotherapy 62 postdose 62 advanced adenoma 62 serum antibody 62 ceftriaxone 62 Linagliptin 62 QTc 62 visilizumab 62 viral kinetic 62 advanced adenomas 62 dose cyclophosphamide 62 insulin glulisine 62 x ULN 62 Actilon 62 pharmacokinetic parameters 62 FOLPI regimen 62 ATACAND 62 cytokine interleukin 62 remifentanil 62 univariate analysis 62 leflunomide 62 voriconazole 62 atorvastatin #mg 62 lumbar spine bone 62 IFN gamma 62 virologically 62 bezafibrate 62 neutralizing antibody 62 tumor xenograft models 62 receiving golimumab 62 #.#mg/kg [002] 62 rilonacept 62 leukopenia 62 endoscopic remission 62 ACZ# 62 hsCRP levels 62 locoregional disease 62 moderate renal impairment 62 serum phosphate 62 protease inhibitor PI 62 prospectively stratified 62 mTOR inhibitors 62 Kaplan Meier estimate 62 Telintra 62 HT 1A 62 MMSE score 62 receiving highly emetogenic 62 neutrophil count 62 COPAXONE R 62 TNF inhibitor 62 taxane chemotherapy 62 subcutaneous insulin 62 dose dependently 62 APOPTONE 62 granisetron 62 Pharmacokinetics PK 62 genotype 1a 62 cynomolgus monkeys 62 talabostat 62 dose dose escalation 62 hypomagnesemia 62 dose proportionality 62 immunoreactivity 62 adecatumumab 62 FLT3 ITD 62 receiving ISENTRESS 62 rituximab monotherapy 62 hour bronchodilation 62 relapsed refractory multiple myeloma 62 nonfatal MI 62 bisoprolol 62 zalutumumab 62 liver histology 62 odanacatib 62 iniparib 62 monotherapy 62 Navelbine 62 histologically 62 saline injections 62 debulking surgery 62 PREZISTA r arm 62 DAS# remission 62 IGFBP 3 62 Gleevec resistant 62 stage IIIb IV 62 adjunctive ABILIFY 62 MIRAPEX 62 macroalbuminuria 62 cEVR 62 locomotor activity 62 placebo controlled Phase 62 atheroma volume 62 locoregional recurrence 62 oral antidiabetic medication 62 TLUS 62 Omacetaxine mepesuccinate 62 statistical significance p 62 subcutaneously injected 62 interferon alfa 2a 62 pegylated interferon 62 fibrinolytic therapy 62 budesonide pMDI 62 ALGRX 62 IU mL 62 azathioprine 62 cardiac toxicity 62 HuMax EGFr 62 viremia 62 ORENCIA ® 62 adefovir treated 62 lenalidomide Revlimid R 62 ZYVOX 62 Viread Emtriva Sustiva 62 cidofovir 62 TAXUS Stent 62 tumor necrosis 62 docetaxel Taxotere ® 62 parathyroid hormone PTH 62 mucosal healing 62 DMARD 62 systemic absorption 62 FOLFOX6 62 baseline A1C 62 plus OBT 62 COPEGUS 62 efavirenz EFV 62 LVEF 62 #.#mg/dL 62 HGS ETR2 62 hematological toxicity 62 pegylated alpha interferon 62 serum aminotransferase levels 62 randomized #:#:# 62 GnRH agonists 62 pharmacokinetic characteristics 62 treatment naïve genotype 62 intradermal injections 62 relapsed CLL 62 oral vancomycin 62 null responder HCV 62 cGy 62 Pegasys plus Copegus 62 NMIBC 61 montelukast 61 retapamulin 61 venlafaxine ER 61 TURBT 61 plus 5-FU/LV 61 Sprague Dawley rats 61 dobutamine 61 hepatitis C genotype 61 SCH # 61 icatibant 61 CRp 61 paclitaxel eluting stents 61 acute GvHD 61 palonosetron 61 aldosterone antagonist 61 nonmetastatic prostate cancer 61 TNFalpha 61 receiving INTRON 61 trabedersen 61 PEG Interferon alfa